title: The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications.
abstract: Dorzolamide is the first commercial topical carbonic anhydrase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of glaucoma. In a prospective, open label, uncontrolled study on 245 glaucoma patients, dorzolamide significantly lowered the intraocular pressure at least 14% when used alone or in combination with one, two, or three other antiglaucoma medications over ten weeks. There were very few adverse reactions to dorzolamide. Dorzolamide is effective and safe when used alone or in combination with other topical antiglaucoma medications for the treatment of glaucoma.
authors.affiliation: Jules Stein Eye Institute, University of California at Los Angeles, 90095-7004, USA.
authors.forename: H H
authors.initials: HH
authors.lastname: Le
authors.forename: M R
authors.initials: MR
authors.lastname: Chang
authors.forename: Q
authors.initials: Q
authors.lastname: Cheng
authors.forename: D A
authors.initials: DA
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Hartenbaum
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide